![]() ![]() Results: Fifty-five consecutive patients were enrolled with a male-to-female ratio of 10:1, the median age was 62 years old (IQR: 45-76), of which 44 patients (80%) were diagnosed with squamous cell carcinoma. The Renaissance study was approved by the Peking University Ethic board (2020YJZ58) and registered at as NCT04606303. The relationship between irAEs and pathological outcomes was analyzed. A multidisciplinary team including physicians, surgeons, and radiologists, confirmed the irAEs according to the clinical manifestation. Data were analyzed to explore the relationship between clinical outcome and irAEs after neoadjuvant treatment. Patients were enrolled if they have resectable IIB-IIIB NSCLC without EGFR/ALK mutation. Methods: We conducted the prospective study of NSCLC patients treated by neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy from December 2020 to March 2022 at Peking University Cancer Hospital. Here we elucidated the early onset of irAEs associated with better clinical outcomes in a prospective study (Renaissance study). Immune-related adverse events (irAEs) have been preliminarily implicated their association with treatment efficacy. Beijing Cancer Hospital, Peking University, Beijing, Chinaīackground: Neoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC).Ye Tao, Xiang Li, Bing Liu, Jia Wang, Chao Lv, Shaolei Li, Yuzhao Wang, Jinfeng Chen, Shi Yan * and Nan Wu * ![]()
0 Comments
Leave a Reply. |